| Style | Citing Format |
|---|---|
| MLA | Sahraian MA, et al.. "Secondary Autoimmune Dermatological Disorders Induced by Multiple Sclerosis Biological Immunotherapy Agents: A Systematic Review of Case Reports." Iranian Journal of Pharmaceutical Research, vol. 24, no. 1, 2025, pp. -. |
| APA | Sahraian MA, Emami S, Ataei S, Nasr Esfahani F, Ghalandari N (2025). Secondary Autoimmune Dermatological Disorders Induced by Multiple Sclerosis Biological Immunotherapy Agents: A Systematic Review of Case Reports. Iranian Journal of Pharmaceutical Research, 24(1), -. |
| Chicago | Sahraian MA, Emami S, Ataei S, Nasr Esfahani F, Ghalandari N. "Secondary Autoimmune Dermatological Disorders Induced by Multiple Sclerosis Biological Immunotherapy Agents: A Systematic Review of Case Reports." Iranian Journal of Pharmaceutical Research 24, no. 1 (2025): -. |
| Harvard | Sahraian MA et al. (2025) 'Secondary Autoimmune Dermatological Disorders Induced by Multiple Sclerosis Biological Immunotherapy Agents: A Systematic Review of Case Reports', Iranian Journal of Pharmaceutical Research, 24(1), pp. -. |
| Vancouver | Sahraian MA, Emami S, Ataei S, Nasr Esfahani F, Ghalandari N. Secondary Autoimmune Dermatological Disorders Induced by Multiple Sclerosis Biological Immunotherapy Agents: A Systematic Review of Case Reports. Iranian Journal of Pharmaceutical Research. 2025;24(1):-. |
| BibTex | @article{ author = {Sahraian MA and Emami S and Ataei S and Nasr Esfahani F and Ghalandari N}, title = {Secondary Autoimmune Dermatological Disorders Induced by Multiple Sclerosis Biological Immunotherapy Agents: A Systematic Review of Case Reports}, journal = {Iranian Journal of Pharmaceutical Research}, volume = {24}, number = {1}, pages = {-}, year = {2025} } |
| RIS | TY - JOUR AU - Sahraian MA AU - Emami S AU - Ataei S AU - Nasr Esfahani F AU - Ghalandari N TI - Secondary Autoimmune Dermatological Disorders Induced by Multiple Sclerosis Biological Immunotherapy Agents: A Systematic Review of Case Reports JO - Iranian Journal of Pharmaceutical Research VL - 24 IS - 1 SP - EP - PY - 2025 ER - |